Adderall Tapering Guide
amphetamine/dextroamphetamine
Boxed Warning
High potential for abuse and dependence. Misuse may cause sudden death and serious cardiovascular adverse events.
Overview
Adderall (mixed amphetamine salts) is a stimulant medication approved for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. It contains a 3:1 ratio of dextroamphetamine to levoamphetamine salts.
IR: 5, 7.5, 10, 12.5, 15, 20, 30mg; XR: 5, 10, 15, 20, 25, 30mg
IR tablets: 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg, 30mg; XR capsules: 5mg, 10mg, 15mg, 20mg, 25mg, 30mg
Category C (risk cannot be ruled out)
Mechanism of Action
Amphetamines increase synaptic dopamine and norepinephrine via reverse transport through DAT and NET, inhibition of monoamine oxidase, and promotion of vesicular release. Effects on prefrontal cortex underlie therapeutic action in ADHD.
Taper Notes
Discontinuation produces rebound fatigue, dysphoria, hyperphagia, and cognitive slowing reflecting catecholamine-receptor downregulation. A staged taper using IR fractions, XR strengths, or compounded liquid mitigates the rebound period. Schedule II controlled substance — document dispensing carefully throughout.
Maudsley Deprescribing Guidance
Stimulant withdrawal is generally not medically dangerous but can be subjectively severe. Apply slow stepwise reductions (~25% every 1–2 weeks); align timing with the patient's functional demands. Monitor mood — depressive symptoms can be marked in the first 2 weeks and warrant active surveillance.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 1-2 weeks | Reduce total daily dose by ~25%. For XR users, convert to IR equivalents to enable finer reductions and better matched dosing schedules. |
| Middle reductions | 2-3 weeks | Continue ~25% reductions every 1–2 weeks. Adjust dosing schedule to match patient functional demands. |
| Lower-dose reductions | 2-4 weeks | Below 10 mg/day, transition to tablet splitting or compounded liquid for smaller increments. Urine pH affects clearance — relevant in patients on alkalinizing or acidifying agents. |
| Final discontinuation | 1-2 weeks | Final cuts to off. Schedule the rebound window during a period of lower demand for the patient. |
Withdrawal Timeline
Hours after the last dose (post-dose crash) or 1-2 days after a dose reduction
3-7 days
Acute rebound resolves within 1-2 weeks
Anhedonia, low motivation, and sleep changes can persist 2-8 weeks
Clinical Pearls
Practical considerations for clinicians supervising Adderall tapers.
- 1Schedule the taper during a period of lower functional demand for the patient — the first 2 weeks post-reduction commonly produce significant fatigue, hyperphagia, and amotivation.
- 2Convert from XR to IR before reducing — IR provides more granular control over the daily dose curve and supports cleaner tapering schedules.
- 3Counsel the patient on sleep prioritization, hydration, and protein-forward nutrition during the rebound window; appetite increase is mechanistic and warrants planning rather than restraint.
- 4For tapers driven by cardiovascular concerns, psychosis risk, or substance-use issues, the pace should be set against clinical urgency rather than patient preference; collaborate closely with cardiology or addiction medicine where indicated.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (hypertensive crisis risk)
- Serotonergic agents (SSRIs, SNRIs, TCAs, tramadol, MDMA) — serotonin syndrome risk
- Antihypertensives — reduced efficacy
Food Interactions
- Acidic foods/juices reduce absorption (citrus, vitamin C)
- Alkalinizing agents (sodium bicarbonate) increase amphetamine levels
- Avoid combining with high-dose caffeine
Contraindications
- Concurrent or recent (within 14 days) MAOI use
- Advanced arteriosclerosis, symptomatic cardiovascular disease
- Moderate-to-severe hypertension
Toxicity
Cardiovascular events (sudden death in patients with structural cardiac abnormalities), psychosis, mania, serotonin syndrome (with serotonergic agents), seizures, severe dependence, and growth suppression in children.
External References
Pharmacokinetics
ADME Profile
IR: Tmax ~3 hours. XR: dual-pulse release, Tmax ~7 hours. Food does not significantly affect total exposure but can delay Tmax.
~3-4 L/kg
Hepatic, primarily via CYP2D6 to 4-hydroxyamphetamine and other metabolites. Some renal excretion of unchanged drug, increased by acidic urine.
Renal (~30% unchanged at neutral urine pH; up to 70% in acidic urine).
~16-20%
Variable, urine pH-dependent
Build Adderall taper plans in minutes
TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.
Try TaperMeds